本帖最后由 老马 于 2012-1-13 21:20 编辑 ) U2 u$ o# }' Q7 z# `+ B/ r9 S% U* W! y
* t/ s! f; r G4 e8 h0 `爱必妥和阿瓦斯丁的比较
$ V) ?; ?$ L- S0 A6 W
/ W4 ~& W, T* ehttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/2 A. a5 |$ {' N& ?6 ]5 }( z5 x
7 \/ @: M4 i2 F$ x3 I6 F
! M, ^0 P& x: @$ r6 s
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
3 _9 v. a3 c, E0 T# C==================================================. |3 |0 M. M# A4 K! J8 [( i$ c0 m A9 x
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)$ O# ^5 t; q- C( Z" ]
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
5 Y" [) B9 _+ V( Z* A! nResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
) {% b" b3 _. H* J# @
|